Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects - A randomized double-blind placebo-controlled crossover study

George B. Kudolo, Wen Wang, Ryan Elrod, Jessica Barrientos, Alexis Haase, Janet Blodgett

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    Background & Aims: Ingestion of Ginkgo biloba Extract (EGb 761) may increase pancreatic β-cell function in both healthy subjects with normal glucose tolerance (NGT) as well as patients with Type 2 Diabetes mellitus (T2DM). Since hyperinsulinemia is a hallmark of T2DM, it is important to verify that increased insulin production is not due to increased insulin resistance. Method: NGT subjects (n = 10; age, 44.2±13.9 years old), impaired glucose tolerance (IGT) (n = 8; age 51.3±6.6 years old) and T2DM subjects (n = 8, 51.6±15.2 years old) completed a randomized, double-blind, placebo-controlled crossover study. After ingesting either EGb 761 (120 mg/day as a single dose) or placebo during each 3-month arm, a 2-step euglycemic insulin clamp was performed. Results: At the low insulin infusion rate (10 mU/m2/min) the glucose metabolic rates (M values) were 3.5±1.5 vs. 3.0±0.5 mg/kg (P = 0.16), 3.0±0.4 vs. 2.8±0.8 mg/kg (P = 0.19) and 2.6±0.7 vs. 2.4±0.5 mg/kg (P = 0.09) for the placebo and EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. At the high insulin infusion rate (40 mU/m2/ min) the M values were 7.3±2.3 vs. 8.1±2.5 mg/kg (P = 0.07), 6.2±1.6 vs. 6.5±2.1 mg/kg (P = 0.32) and 3.6±1.6 vs. 3.5±1.0 mg/kg (P = 0.34) for placebo vs. EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. Conclusion: The ingestion of 120 mg of EGb 761 as a single for 3 months did not produce insulin resistance in the non-diabetic or pre-diabetic subjects or exacerbate the disease in the T2DM subjects.

    Original languageEnglish (US)
    Pages (from-to)123-134
    Number of pages12
    JournalClinical Nutrition
    Volume25
    Issue number1
    DOIs
    StatePublished - Feb 2006

    Fingerprint

    Ginkgo biloba
    Cross-Over Studies
    Type 2 Diabetes Mellitus
    Insulin Resistance
    Eating
    Placebos
    Glucose Intolerance
    Glucose
    Insulin
    Glucose Clamp Technique
    Hyperinsulinism
    Ginkgo biloba extract 761
    Healthy Volunteers

    Keywords

    • Ginkgo biloba
    • Insulin resistance
    • Type 2 diabetes

    ASJC Scopus subject areas

    • Critical Care and Intensive Care Medicine
    • Endocrinology, Diabetes and Metabolism
    • Gastroenterology
    • Health Professions(all)
    • Medicine (miscellaneous)

    Cite this

    Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects - A randomized double-blind placebo-controlled crossover study. / Kudolo, George B.; Wang, Wen; Elrod, Ryan; Barrientos, Jessica; Haase, Alexis; Blodgett, Janet.

    In: Clinical Nutrition, Vol. 25, No. 1, 02.2006, p. 123-134.

    Research output: Contribution to journalArticle

    @article{c5bb0d02f077400d97b80b3a872e856c,
    title = "Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects - A randomized double-blind placebo-controlled crossover study",
    abstract = "Background & Aims: Ingestion of Ginkgo biloba Extract (EGb 761) may increase pancreatic β-cell function in both healthy subjects with normal glucose tolerance (NGT) as well as patients with Type 2 Diabetes mellitus (T2DM). Since hyperinsulinemia is a hallmark of T2DM, it is important to verify that increased insulin production is not due to increased insulin resistance. Method: NGT subjects (n = 10; age, 44.2±13.9 years old), impaired glucose tolerance (IGT) (n = 8; age 51.3±6.6 years old) and T2DM subjects (n = 8, 51.6±15.2 years old) completed a randomized, double-blind, placebo-controlled crossover study. After ingesting either EGb 761 (120 mg/day as a single dose) or placebo during each 3-month arm, a 2-step euglycemic insulin clamp was performed. Results: At the low insulin infusion rate (10 mU/m2/min) the glucose metabolic rates (M values) were 3.5±1.5 vs. 3.0±0.5 mg/kg (P = 0.16), 3.0±0.4 vs. 2.8±0.8 mg/kg (P = 0.19) and 2.6±0.7 vs. 2.4±0.5 mg/kg (P = 0.09) for the placebo and EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. At the high insulin infusion rate (40 mU/m2/ min) the M values were 7.3±2.3 vs. 8.1±2.5 mg/kg (P = 0.07), 6.2±1.6 vs. 6.5±2.1 mg/kg (P = 0.32) and 3.6±1.6 vs. 3.5±1.0 mg/kg (P = 0.34) for placebo vs. EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. Conclusion: The ingestion of 120 mg of EGb 761 as a single for 3 months did not produce insulin resistance in the non-diabetic or pre-diabetic subjects or exacerbate the disease in the T2DM subjects.",
    keywords = "Ginkgo biloba, Insulin resistance, Type 2 diabetes",
    author = "Kudolo, {George B.} and Wen Wang and Ryan Elrod and Jessica Barrientos and Alexis Haase and Janet Blodgett",
    year = "2006",
    month = "2",
    doi = "10.1016/j.clnu.2005.10.001",
    language = "English (US)",
    volume = "25",
    pages = "123--134",
    journal = "Clinical Nutrition",
    issn = "0261-5614",
    publisher = "Churchill Livingstone",
    number = "1",

    }

    TY - JOUR

    T1 - Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects - A randomized double-blind placebo-controlled crossover study

    AU - Kudolo, George B.

    AU - Wang, Wen

    AU - Elrod, Ryan

    AU - Barrientos, Jessica

    AU - Haase, Alexis

    AU - Blodgett, Janet

    PY - 2006/2

    Y1 - 2006/2

    N2 - Background & Aims: Ingestion of Ginkgo biloba Extract (EGb 761) may increase pancreatic β-cell function in both healthy subjects with normal glucose tolerance (NGT) as well as patients with Type 2 Diabetes mellitus (T2DM). Since hyperinsulinemia is a hallmark of T2DM, it is important to verify that increased insulin production is not due to increased insulin resistance. Method: NGT subjects (n = 10; age, 44.2±13.9 years old), impaired glucose tolerance (IGT) (n = 8; age 51.3±6.6 years old) and T2DM subjects (n = 8, 51.6±15.2 years old) completed a randomized, double-blind, placebo-controlled crossover study. After ingesting either EGb 761 (120 mg/day as a single dose) or placebo during each 3-month arm, a 2-step euglycemic insulin clamp was performed. Results: At the low insulin infusion rate (10 mU/m2/min) the glucose metabolic rates (M values) were 3.5±1.5 vs. 3.0±0.5 mg/kg (P = 0.16), 3.0±0.4 vs. 2.8±0.8 mg/kg (P = 0.19) and 2.6±0.7 vs. 2.4±0.5 mg/kg (P = 0.09) for the placebo and EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. At the high insulin infusion rate (40 mU/m2/ min) the M values were 7.3±2.3 vs. 8.1±2.5 mg/kg (P = 0.07), 6.2±1.6 vs. 6.5±2.1 mg/kg (P = 0.32) and 3.6±1.6 vs. 3.5±1.0 mg/kg (P = 0.34) for placebo vs. EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. Conclusion: The ingestion of 120 mg of EGb 761 as a single for 3 months did not produce insulin resistance in the non-diabetic or pre-diabetic subjects or exacerbate the disease in the T2DM subjects.

    AB - Background & Aims: Ingestion of Ginkgo biloba Extract (EGb 761) may increase pancreatic β-cell function in both healthy subjects with normal glucose tolerance (NGT) as well as patients with Type 2 Diabetes mellitus (T2DM). Since hyperinsulinemia is a hallmark of T2DM, it is important to verify that increased insulin production is not due to increased insulin resistance. Method: NGT subjects (n = 10; age, 44.2±13.9 years old), impaired glucose tolerance (IGT) (n = 8; age 51.3±6.6 years old) and T2DM subjects (n = 8, 51.6±15.2 years old) completed a randomized, double-blind, placebo-controlled crossover study. After ingesting either EGb 761 (120 mg/day as a single dose) or placebo during each 3-month arm, a 2-step euglycemic insulin clamp was performed. Results: At the low insulin infusion rate (10 mU/m2/min) the glucose metabolic rates (M values) were 3.5±1.5 vs. 3.0±0.5 mg/kg (P = 0.16), 3.0±0.4 vs. 2.8±0.8 mg/kg (P = 0.19) and 2.6±0.7 vs. 2.4±0.5 mg/kg (P = 0.09) for the placebo and EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. At the high insulin infusion rate (40 mU/m2/ min) the M values were 7.3±2.3 vs. 8.1±2.5 mg/kg (P = 0.07), 6.2±1.6 vs. 6.5±2.1 mg/kg (P = 0.32) and 3.6±1.6 vs. 3.5±1.0 mg/kg (P = 0.34) for placebo vs. EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. Conclusion: The ingestion of 120 mg of EGb 761 as a single for 3 months did not produce insulin resistance in the non-diabetic or pre-diabetic subjects or exacerbate the disease in the T2DM subjects.

    KW - Ginkgo biloba

    KW - Insulin resistance

    KW - Type 2 diabetes

    UR - http://www.scopus.com/inward/record.url?scp=33144470037&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33144470037&partnerID=8YFLogxK

    U2 - 10.1016/j.clnu.2005.10.001

    DO - 10.1016/j.clnu.2005.10.001

    M3 - Article

    C2 - 16293352

    AN - SCOPUS:33144470037

    VL - 25

    SP - 123

    EP - 134

    JO - Clinical Nutrition

    JF - Clinical Nutrition

    SN - 0261-5614

    IS - 1

    ER -